瑞士Biocartis 
Biocartis 创立于2007年，是一家私营生物技术公司。其创始人为鲁迪.鲍威尔博士、菲利浦.雷诺教授和内德.东泽尔。Biocartis 致力于开发新诊断技术平台，为不同复杂程度的分子生物指标检测服务。公司计划于2012年将多功能及精巧分子诊断平台推向市场。该平台操作简便，将降低分子诊断测试的准入壁垒。它位于瑞士洛桑联邦理工大学的科技园以及荷兰埃因霍温技术学院内。

公司自2009年以来获得了来自一些财团的巨额投资， 其中包括一些欧洲最成功的生物公司企业家投资，例如Aescap风险管理、Advent 风险投资公司、Biovest, Bebiopharm 集团以及KBC私募基金公司和Johnson & Johnson开发公司。

Biocartis aims to transform the global diagnostics market by making personalized medicine an everyday reality. The challenge Biocartis addresses is to enable the broadest possible access to new technologies that will allow individual diagnoses to be made quickly based on a systematic analysis of the wealth of rapidly emerging biomarkers rather than solely on physiological symptoms as they are today. Ending the ‘one drug fits all’ paradigm will empower physicians to make better diagnoses based on better information leading to better treatment outcomes and the more efficient use of precious healthcare resources.

Biocartis intends to become a fully integrated provider of novel, broadly applicable molecular diagnostics and immunodiagnostics solutions (instruments, analytical techniques, chemistries, sample preparation and other innovative tools) with high-value clinical assay menus. These solutions are designed to be compatible with deployment in a wide variety of health care settings, providing rapid, high-quality care close to the patient. Biocartis’ vision is shared by its current collaborators which include bioMérieux and Janssen Pharmaceutica (J&J).
Biocartis is currently developing two innovative systems that share a common user interface and design philosophy:

A Molecular Diagnostics Platform system is designed for the MDx market, comprising an instrument, communication console and single use, disposable cartridges. This system can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with truly minimal user intervention.
A Multiplex Detection Platform that has been built around disposable, microfluidic cartridges with digitally encoded microparticles for the rapid and sensitive detection of a broad range and number of biomarkers. The first product from this technology will focus on protein-based biomarkers and will allow Biocartis to enter the immunoassay market.
Biocartis was founded in 2007 by Dr. Rudi Pauwels (Co-founder of Tibotec, Virco and Galapagos Genomics), Prof. Philippe Renaud (Prof. at EPFL), and Nader Donzel (Co-founder of Scitec laboratory Automation). The company has raised more than €100 million in equity funding.
Biocartis SA is based at the EPFL's Innovation Square in Lausanne, Switzerland; it has a fully owned Belgian subsidiary in Mechelen and a Dutch subsidiary at the High Tech Campus in Eindhoven.